menu
    • menu
    [{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"SDIC Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"RAG-06","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ractigen Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ SDIC Venture Capital","highestDevelopmentStatusID":"5","companyTruncated":"Ractigen Therapeutics \/ SDIC Venture Capital"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RAG-17","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RAG-17","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"saRNA-based Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ University Medical Center Utrecht","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ University Medical Center Utrecht"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"RAG-01","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RAG-01","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RAG-17","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RAG-18","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RAG-18","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RAG-17","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RAG-21","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Ractigen Therapeutics

    Menu

    Ractigen Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-21

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Gains FDA Orphan Designation for RAG-21 in ALS Therapy Development

                            Details : RAG-21, its novel siRNA therapy targeting the FUS gene by reducing its level, for the treatment of FUS-amyotrophic lateral sclerosis

                            Brand Name : RAG-21

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 19, 2024

                            Lead Product(s) : RAG-21

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Announces Positive Data For RAG-17 in ALS-SOD1 Treatment

                            Details : RAG-17 is a small interfering RNA (siRNA) targeting the Superoxide Dismutase 1 (SOD1) gene in the treatment of amyotrophic lateral sclerosis (ALS) associated with SOD1 mutations (ALS-SOD1).

                            Brand Name : RAG-17

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 10, 2024

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-18

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Receives FDA Orphan Drug Designation for RAG-18 in DMD and BMD

                            Details : RAG-18 is a first of its kind saRNA candidate designed to specifically target and activate UTRN gene expression. It is being evaluated for duchenne muscular dystrophy & becker muscular dystrophy.

                            Brand Name : RAG-18

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 22, 2024

                            Lead Product(s) : RAG-18

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-18

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Receives FDA Pediatric Disease Designation for RAG-18 in Duchenne Dystrophy

                            Details : RAG-18 is a first of its kind saRNA candidate designed to specifically target and activate UTRN gene expression. It is being evaluated for duchenne muscular dystrophy & becker muscular dystrophy.

                            Brand Name : RAG-18

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 25, 2024

                            Lead Product(s) : RAG-18

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy

                            Details : RAG-01 stands as a pioneering saRNA candidate from Ractigen Therapeutics, engineered to target and activate the tumor suppressor gene p21, intended for non-muscle-invasive bladder cancer.

                            Brand Name : RAG-01

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 21, 2024

                            Lead Product(s) : RAG-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Therapeutics Receives IND Approval for Phase 1 Trials of RAG-17 in ALS

                            Details : RAG-17 is a therapeutic siRNA specifically designed to suppress the SOD1 gene in Amyotrophic Lateral Sclerosis patients carrying the Superoxide Dismutase 1 (SOD1) mutation.

                            Brand Name : RAG-17

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 15, 2024

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : saRNA-based Therapy

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : University Medical Center Utrecht

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ractigen Partners with University Medical Center Utrecht to Advance saRNA in Disorders

                            Details : This strategic alliance unites their respective strengths to advance the development of saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 29, 2024

                            Lead Product(s) : saRNA-based Therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : University Medical Center Utrecht

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

                            Details : RAG-01 stands as a pioneering saRNA candidate from Ractigen Therapeutics, engineered to target and activate the tumor suppressor gene p21, intended for non-muscle-invasive bladder cancer.

                            Brand Name : RAG-01

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 06, 2023

                            Lead Product(s) : RAG-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of...

                            Details : RAG-17 is a siRNA drug designed to provide potent and durable knockdown of SOD1 protein in the central nervous system (CNS) of ALS patients to prevent motor neuron degradation and delay disease progression.

                            Brand Name : RAG-17

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Ractigen Therapeutics

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ractigen Therapeutics Receives FDA Orphan Drug Designation For the Novel Oligonucleotide Conjugate RAG-17 for ...

                            Details : RAG-17 is a therapeutic siRNA designed to target and knockdown the expression of SOD1 gene in patients with pathogenic mutations known to cause amyotrophic lateral sclerosi.

                            Brand Name : RAG-17

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 03, 2023

                            Lead Product(s) : RAG-17

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth